Protagonist Therapeutics shares traded lower as investors digested a new insider-trading disclosure showing CEO Dinesh V. Patel exercised options and then sold stock in late March. The Form 4 details the exercise of options into 54,700 shares at an $8.58 strike price and the sale of 54,700 shares at about $101 per share, reported over March 24–25, 2026, alongside a separate gift of 50,000 shares dated March 23, 2026.

In a biotech name that has rallied strongly, a large, highly visible executive sale can act as a near-term overhang, especially when the stock is trading near recent highs. Even when sales are associated with option exercises, the optics of monetization can pressure sentiment and prompt short-term traders to lock in gains.

The move comes shortly after a major catalyst: on March 18, 2026, ICOTYDE (icotrokinra) won U.S. FDA approval for moderate-to-severe plaque psoriasis in adults and pediatric patients ages 12+ who weigh at least 40 kg, with Johnson & Johnson responsible for commercialization. That approval triggered a $50 million milestone payment to Protagonist, reinforcing the company’s transition toward commercial-stage economics and helping fuel the prior advance that’s now being consolidated.